A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT05091346
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Providence Medical Center, Portland, Oregon, United States
A Study of Subcutaneous Lecanemab in Healthy Participants
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05045716
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT04971733
- Locations
- 🇺🇸
UC San Diego Altman Clinical and Translational Research Insititute Clinic, La Jolla, California, United States
🇬🇧National Hospital for Neurology and Neurosurgery (NHNN) University College London(UCL) Hospitals NHS Foundation Trust, London, United Kingdom
🇺🇸Indiana University School of Medicine, Health Partners, Adult Neurology Clinic, Indianapolis, Indiana, United States
A Study to Evaluate Lemborexant in Milk of Healthy Lactating Women
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT04890561
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Las Vegas, Nevada, United States
A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 335
- Registration Number
- NCT04763408
- Locations
- 🇺🇸
California Liver Research Institute, Pasadena, California, United States
🇩🇪Eisai Trial Site #2, Berlin, Germany
🇩🇪Eisai Trial Site #6, Munich, Germany
A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT04764669
- Locations
- 🇺🇸
JEM Research Institute, Atlantis, Florida, United States
🇺🇸University of South Florida, Department of Psychiatry and Behavioral Neurosciences, Tampa, Florida, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
A Study to Assess the Safety and Tolerability of E2730 After Multiple Dose and the Food Effect After Single Dose in Healthy Participants
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2021-08-26
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT04676685
- Locations
- 🇺🇸
Collaborative Neuroscience Research, LLC., Long Beach, California, United States
A Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Participants With Moderate to Severe Obstructive Sleep Apnea, and in Adult and Elderly Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2020-11-30
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT04647383
- Locations
- 🇺🇸
Pacific Research Network, San Diego, California, United States
🇺🇸St. Francis Medical Institute, Clearwater, Florida, United States
🇺🇸NeuroTrials Research Inc., Atlanta, Georgia, United States
A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT04572243
- Locations
- 🇺🇸
Children's of Alabama / University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of California Los Angeles (UCLA), Los Angeles, California, United States
🇺🇸UCSD Rady's Children's Hosptial, San Diego, California, United States
A Study to Assess the Safety and Tolerability of E2511 in Healthy Participants
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT04547361
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States